Literature DB >> 25488785

Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs.

Enrique Roberto Soriano1, Maria Laura Acosta-Felquer2, Phat Luong3, Liron Caplan4.   

Abstract

This manuscript focuses on the pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis - including ankylosing spondylitis - using traditional biologic and non-biologic disease-modifying antirheumatic drugs. Early treatment of psoriatic arthritis and axial spondyloarthritis/ankylosing spondylitis as well as the treat-to-target concept receive particular attention. This review also surveys recent national and international guidelines for the treatment of both psoriatic arthritis and couches practice recommendations for axial spondyloarthritis/ankylosing spondylitis within the context of various international guidelines. Published by Elsevier Ltd.

Entities:  

Keywords:  Ankylosing; Arthritis; Biological therapies; NLM MeSH terms; Psoriatic; Spondylitis; Therapeutics

Mesh:

Substances:

Year:  2014        PMID: 25488785     DOI: 10.1016/j.berh.2014.10.011

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  2 in total

Review 1.  An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy.

Authors:  María Laura Acosta-Felquer; Javier Rosa; Enrique R Soriano
Journal:  Open Access Rheumatol       Date:  2016-03-30

2.  Clinical Characteristics of Patients With Psoriatic Spondylitis Versus Those With Ankylosing Spondylitis: Features at Baseline Before Biologic Therapy.

Authors:  Hyoun-Ah Kim; Eunyoung Lee; So Young Park; Shin-Seok Lee; Kichul Shin
Journal:  J Korean Med Sci       Date:  2022-08-22       Impact factor: 5.354

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.